The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease

被引:195
作者
Hage, Fadi G. [1 ,2 ]
Venkataraman, Rajesh [1 ]
Zoghbi, Gilbert J. [1 ,2 ]
Perry, Gilbert J. [1 ]
DeMattos, Angelo M. [3 ]
Iskandrian, Ami E. [1 ]
机构
[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA
[2] Birmingham Vet Adm Med Ctr, Cardiol Sect, Birmingham, AL USA
[3] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA
关键词
chronic kidney disease; coronary heart disease; imaging; revascularization; STAGE RENAL-DISEASE; C-REACTIVE PROTEIN; SUDDEN CARDIAC DEATH; QUALITY-OF-LIFE; INTENSIVE PERIOPERATIVE DIALYSIS; LEFT-VENTRICULAR HYPERTROPHY; CARDIOVASCULAR RISK-FACTORS; NATIONAL-HEALTH; MORTALITY RISK; HEMODIALYSIS-PATIENTS;
D O I
10.1016/j.jacc.2009.02.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) affects approximately 13% of the U. S. population and is associated with increased risk of cardiovascular complications. Once renal replacement therapy became available, it became apparent that the mode of death of patients with advanced CKD was more likely than not related to cardiovascular compromise. Further observation revealed that such compromise was related to myocardial disease (related to hypertension, stiff vessels, coronary heart disease, or uremic toxins). Early on, the excess of cardiovascular events was attributed to accelerated atherosclerosis, inadequate control of blood pressure, lipids, or inflammatory cytokines, or perhaps poor glycemia control. In more recent times, outcome research has given us further information that relates even lesser degrees of renal compromise to an excess of cardiovascular events in the general population and in those with already present atherosclerotic disease. As renal function deteriorates, certain physiologic changes occur (perhaps due to hemodynamic, inflammatory, or metabolic changes) that decrease oxygen-carrying capacity of the blood by virtue of anemia, make blood vessels stiffer by altering collagen or through medial calcinosis, raise the blood pressure, increase shearing stresses, or alter the constituents of atherosclerotic plaque or the balance of thrombogenesis and thrombolysis. At further levels of renal dysfunction, tangible metabolic perturbations are recognized as requiring specific therapy to reduce complications (such as for anemia and hyperparathyroidism), although outcome research to support some of our current guidelines is sorely lacking. Understanding the process by which renal dysfunction alters the prognosis of cardiac disease might lead to further methods of treatment. This review will outline the relationship of CKD to coronary heart disease with respect to the current understanding of the traditional and nontraditional risk factors, the role of various imaging modalities, and the impact of coronary revascularization on outcome. (J Am Coll Cardiol 2009;53:2129-40) (C) 2009 by the American College of Cardiology Foundation
引用
收藏
页码:2129 / 2140
页数:12
相关论文
共 125 条
[1]  
[Anonymous], 2003, Am J Kidney Dis, V41, pI
[2]  
[Anonymous], 2008, Am J Kidney Dis, V51, pS1
[3]   Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Moons, P ;
Borm, G ;
Hilbrands, LB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :937-945
[4]   Association of kidney function with anemia - The Third National Health and Nutrition Examination Survey (1988-1994) [J].
Astor, BC ;
Muntner, P ;
Levin, A ;
Eustace, JA ;
Coresh, J .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (12) :1401-1408
[5]   Erythropoietin regulates endothelial progenitor cells [J].
Bahlmann, FH ;
de Groot, K ;
Spandau, JM ;
Landry, AL ;
Hertel, B ;
Duckett, T ;
Boehm, SM ;
Menne, J ;
Haller, H ;
Fliser, D .
BLOOD, 2004, 103 (03) :921-926
[6]   High-sensitivity C-reactive protein: Clinical importance [J].
Bassuk, SS ;
Rifai, N ;
Ridker, PM .
CURRENT PROBLEMS IN CARDIOLOGY, 2004, 29 (08) :439-493
[7]   Cardiac surgery in patients on dialysis:: Decreased 30-day mortality, unchanged overall survival [J].
Bechtel, J. F. Matthias ;
Detter, Christian ;
Fischlein, Theodor ;
Krabatsch, Thomas ;
Osswald, Brigitte R. ;
Riss, Friedrich-Christian ;
Scholz, Fridtjof ;
Schoenburg, Markus ;
Stamm, Christof ;
Sievers, Hans-Hinrich ;
Bartels, Claus .
ANNALS OF THORACIC SURGERY, 2008, 85 (01) :147-153
[8]   Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III) [J].
Belonje, Anne M. ;
Voors, Adriaan A. ;
van Gilst, Wiek H. ;
Anker, Stefan D. ;
Slart, Riemer H. ;
Tio, Rene A. ;
Zijlstra, Felix ;
van Veldhuisen, Dirk J. .
AMERICAN HEART JOURNAL, 2008, 155 (05) :817-822
[9]   Kidney-heart interactions: Epidemiology, pathogenesis, and treatment [J].
Berl, Tomas ;
Henrich, William .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (01) :8-18
[10]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590